Enzyme Replacement Therapy and Fabry Nephropathy

David G. Warnock; Erica Daina; Giuseppe Remuzzi; Michael West

doi:10.2215/cjn.06900909

journal article Feb 01, 2010

Enzyme Replacement Therapy and Fabry Nephropathy

David G. Warnock Erica Daina Giuseppe Remuzzi

Michael West

Clinical Journal of the American Society of Nephrology Vol. 5 No. 2 pp. 371-378 · Ovid Technologies (Wolters Kluwer Health)

View at Publisher Save 10.2215/cjn.06900909

Topics

No keywords indexed for this article. Browse by subject →

References

44

[1]

Gubler "Early renal changes in hemizygous and heterozygous patients with Fabry's disease" Kidney Int (1978) 10.1038/ki.1978.32

[2]

Sessa "Renal pathological changes in Fabry disease" J Inherit Metab Dis (2001) 10.1023/a:1012423924648

[3]

Thurberg "Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy." Kidney Int (2002) 10.1046/j.1523-1755.2002.00675.x

[4]

Tondel "Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria" Am J Kidney Dis (2008) 10.1053/j.ajkd.2007.12.032

[5]

Valbuena "Kidney biopsy findings in heterozygous Fabry disease females with early nephropathy" Virchows Arch (2008) 10.1007/s00428-008-0653-2

[6]

Alroy "Renal pathology in Fabry disease" J Am Soc Nephrol (2002) 10.1097/01.asn.0000016684.07368.75

[7]

MacDermot "Anderson-Fabry disease: Clinical manifestations and impact of disease in a cohort of 98 hemizygous males" J Med Genet (2001) 10.1136/jmg.38.11.750

[8]

Schiffmann "Fabry disease: Progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy" Nephrol Dial Transplant (2009) 10.1093/ndt/gfp031

[9]

Ortiz "Nephropathy in males and females with Fabry disease: Cross-sectional description of patients before treatment with enzyme replacement therapy" Nephrol Dial Transplant (2008) 10.1093/ndt/gfm848

[10]

Schiffmann "Enzyme replacement therapy in Fabry disease: A randomized controlled trial" JAMA (2001) 10.1001/jama.285.21.2743

[11]

Eng "A phase 1/2 clinical trial of enzyme replacement in Fabry disease: Pharmacokinetic, substrate clearance, and safety studies" Am J Hum Genet (2001) 10.1086/318809

[12]

Banikazemi "Agalsidase-beta therapy for advanced Fabry disease: A randomized trial" Ann Intern Med (2007) 10.7326/0003-4819-146-2-200701160-00148

[13]

Schiffmann "Weekly enzyme replacement therapy may slow decline of renal function in Fabry patients who are on long-term biweekly dosing" J Am Soc Nephrol (2007) 10.1681/asn.2006111263

[14]

Warnock "Fabry disease: Diagnosis and management, with emphasis on the renal manifestations" Curr Opin Nephrol Hypertens (2005) 10.1097/00041552-200503000-00002

[15]

Fervenza "Safety and efficacy of enzyme replacement therapy in the nephropathy of Fabry disease" Biologics (2008)

[16]

Feriozzi "Agalsidase alfa slows the decline in renal function in patients with Fabry disease" Am J Nephrol (2009) 10.1159/000168482

[17]

West "Agalsidase alfa and kidney dysfunction in Fabry disease" J Am Soc Nephrol (2009) 10.1681/asn.2008080870

[18]

Levey "Clinical practice: Nondiabetic kidney disease" N Engl J Med (2002) 10.1056/nejmcp013462

[19]

Germain "Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease" J Am Soc Nephrol (2007) 10.1681/asn.2006080816

[20]

Stevens "Assessing kidney function: Measured and estimated glomerular filtration rate" N Engl J Med (2006) 10.1056/nejmra054415

[21]

Schwarting "Enzyme replacement therapy and renal function in 201 patients with Fabry disease" Clin Nephrol (2006)

[22]

Breunig "Clinical benefit of enzyme replacement therapy in Fabry disease" Kidney Int (2006) 10.1038/sj.ki.5000208

[23]

Ruggenenti "Progression, remission, regression of chronic renal diseases" Lancet (2001) 10.1016/s0140-6736(00)04728-0

[24]

Lea "The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: Results of the African American Study of Kidney Disease and Hypertension" Arch Intern Med (2005) 10.1001/archinte.165.8.947

[25]

Ruggenenti "Retarding progression of chronic renal disease: The neglected issue of residual proteinuria" Kidney Int (2003) 10.1046/j.1523-1755.2003.00033.x

[26]

Ruggenenti "Role of remission clinics in the longitudinal treatment of CKD" J Am Soc Nephrol (2008) 10.1681/asn.2007090970

[27]

Tahir "Antiproteinuric therapy and Fabry nephropathy: Sustained reduction in proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta" J Am Soc Nephrol (2007) 10.1681/asn.2006121400

[28]

Schiffmann "Long-term therapy with agalsidase alfa for Fabry disease: Safety and effects on renal function in a home infusion setting" Nephrol Dial Transplant (2006) 10.1093/ndt/gfi152

[29]

Schiffmann "Biomarkers of Fabry disease nephropathy" Clin J Am Soc Nephrol (2010) 10.2215/cjn.06090809

[30]

Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy

Barry M. Brenner, Mark E. Cooper, Dick de Zeeuw et al.

New England Journal of Medicine 2001 10.1056/nejmoa011161

[31]

Lewis "Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with neuropathy due to type 2 diabetes" N Engl J Med (2001) 10.1056/nejmoa011303

[32]

Hofstetter "Prevention of end-stage renal disease due to type 2 diabetes" N Engl J Med (2001) 10.1056/nejm200109203451209

[33]

Remuzzi "Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes" J Clin Invest (2006) 10.1172/jci27699

[34]

Ortiz "Recommendations and guidelines for the diagnosis and treatment of Fabry nephropathy in adults" Nat Clin Pract Nephrol (2008) 10.1038/ncpneph0806

[35]

Eng "Fabry disease: Guidelines for the evaluation and management of multi-organ system involvement" Genet Med (2006) 10.1097/01.gim.0000237866.70357.c6

[36]

A New Equation to Estimate Glomerular Filtration Rate

Andrew S. Levey, Lesley A. Stevens, Christopher H. Schmid et al.

Annals of Internal Medicine 2009 10.7326/0003-4819-150-9-200905050-00006

[37]

Jain "Mineralocorticoid receptor blockers and chronic kidney disease" Clin J Am Soc Nephrol (2009) 10.2215/cjn.01340209

[38]

Kent "Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease." J Am Soc Nephrol (2007) 10.1681/asn.2006101081

[39]

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

Aram V. Chobanian

JAMA 2003 10.1001/jama.289.19.2560

[40]

Kleinert "Prevalence of uncontrolled hypertension in patients with Fabry disease" Am J Hypertens (2006) 10.1016/j.amjhyper.2006.01.011

[41]

Angiotensin-Converting Enzyme Inhibitor–Associated Elevations in Serum Creatinine

George L. Bakris, Matthew R. Weir

Archives of Internal Medicine 2000 10.1001/archinte.160.5.685

[42]

Vedder "Treatment of Fabry disease with different dosing regimens of agalsidase: Effects on antibody formation and GL-3" Mol Genet Metab (2008) 10.1016/j.ymgme.2008.03.003

[43]

Wang "Neutralizing antibodies to therapeutic enzymes: Considerations for testing, prevention and treatment" Nat Biotechnol (2008) 10.1038/nbt.1484

[44]

Young "Is globotriaosylceramide a useful biomarker in Fabry disease?" Acta Paediatr Suppl (2005) 10.1080/08035320510028111

Metrics

19

Citations

44

References

Details

Published: Feb 01, 2010
Vol/Issue: 5(2)
Pages: 371-378

Authors

Cite This Article

David G. Warnock, Erica Daina, Giuseppe Remuzzi, et al. (2010). Enzyme Replacement Therapy and Fabry Nephropathy. Clinical Journal of the American Society of Nephrology, 5(2), 371-378. https://doi.org/10.2215/cjn.06900909

Enzyme Replacement Therapy and Fabry Nephropathy

You May Also Like